Drug Development

Supriya Bhide is a graduate student at the Department of Pharmaceutics and Drug Delivery, University of Mississippi, MS.

Apoorva Panda is a graduate student at the Department of Pharmaceutics and Drug Delivery, University of Mississippi, MS.

S. Rangappa is a research scientist at the Department of Pharmaceutics and Drug Delivery, University of Mississippi, MS.

Abhishek Shettar is a research scientist at the Department of Pharmaceutics and Drug Delivery, University of Mississippi, MS.

M.A. Repka is professor and chair at the Department of Pharmaceutics and Drug Delivery, University of Mississippi, MS.

Rosa Maria Badani Prado is a graduate student at the Dave C. Swalm School of Chemical Engineering, Mississippi State University, MS.

S. Kundu is associate professor at the Dave C. Swalm School of Chemical Engineering, Mississippi State University, MS.

Norman Richardson is technical sales manager at BASF Pharma Solutions, Florham Park, NJ.

S. Narasimha Murthy is professor of Pharmaceutics and Drug Delivery at the University of Mississippi, MS, founder-director of the Institute for Drug Delivery and Biomedical Research, Bangalore, Karnataka, India, and chief scientific officer, Topical Products Testing LLC, University, MS.

Articles

Study results indicate that fatty alcohols may plausibly enhance the skin permeation of clotrimazole.

Evaluating the Impact of Fatty Alcohols on Permeation of Clotrimazole from Topical Creams

Jennifer Markarian is a contributing editor for 

The COVID-19 pandemic has accelerated the need for modular designs to rapidly expand vaccine production capacity.

Modular Processes and Facilities Enable Flexible Vaccine Manufacturing

The investment will expand and upgrade manufacturing capacity and technology for pre-fillable syringes and will also includes a new manufacturing facility in Europe. 

BD to Invest $1.2 Billion Over Four Years in Pre-Fillable Syringe Manufacturing Capacity 

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Transparency and open-dialogue are vital to sway the vaccine-hesitant community.

The COVID-19 Vaccine Blind Spot

Moderna has filed for authorization for its COVID-19 vaccine candidate, which has shown high efficacy and safety in a Phase III trial.

Moderna Files for FDA EUA for mRNA-1273

Behzad Mahdavi, PhD, will join a team of experts in the company’s Science and Technology Group to fast-track the adoption of new development and drug delivery technologies and manufacturing processes and techniques.



Catalent Appoints New Vice President of Open Innovation, Biologics, Cell and Gene Therapy

Wacker will support production of CureVac’s COVID-19 mRNA-based vaccine candidate at its biotech site in Amsterdam, with production scheduled to start in the first half of 2021.

CureVac and Wacker Sign Manufacturing Contract for COVID-19 Vaccine Candidate

The EC’s approval comes after positive results from seven Phase II and III randomized, active-controlled, multi-center studies.

EC Approves Sanofi’s Meningococcal Meningitis Vaccine 

HMA and EMA have released a joint statement on the appropriate route for companies to submit marketing authorization applications and the approval processes for vaccines.

HMA and EMA Release Joint Statement on the Approval of Vaccines

An independent data safety monitoring board found that clinical trial data demonstrated that the vaccine candidate met its primary endpoint and demonstrated protection from COVID-19.

Formulation and Drug Delivery